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Boston, MA. (Sponsored by Jonathan M. Goldstein, Department of Neurology, Hospital for Special 
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Electrical impedance myography (EIM) and quantitative ultrasound (QUS) represent two rapid, 
non-invasive, quantitative, and child-friendly approaches to measure disease outcomes in clinical trials that 
may surpass functional tests currently in use. In this thesis, we present a comparison of EIM and QUS data 
in six muscles from 25 DMD and 25 healthy subjects, aged 2-14 years. Quantitative ultrasound data can be 
analyzed by measuring the brightness, or grayscale level (GSL), of the ultrasound image. To circumvent 
post-processing variability across manufacturers, for the first time, we introduce a new means of evaluating 
QUS—a quantitative backscatter analysis (QBA) on the raw radio frequency (RF) signal received by the 
ultrasound probe in DMD and control subjects. For EIM, either the phase at 50 kHz or the phase ratio (50 
kHz/200 kHz) was used for measuring disease status. We found that taking the phase ratio substantially 
reduces the confounding effect of subcutaneous fat thickness on EIM (r=0.16, p=0.45) compared with the 
standard phase at 50 kHz (r=-0.72, p<0.0001) in averaged muscles. Using age as a surrogate for disease 
severity, we found that 50 kHz phase decreased with age in select muscles while GSL did not. The 
averaged phase correlated strongly with the North Star Ambulatory Assessment (NSAA) (rho=0.735, 
p=0.004), while GSL did not (rho=-0.442, p=0.115). Although the standard phase at 50 kHz averaged 
values did not correlate with GSL, the phase ratio did (rho=-0.48, p=0.017). In DMD, age showed 
comparable correlation with “superficial” region of interest (ROI) QBA and GSL (average: rho=0.67, 
p=0.0004 vs. rho=0.47, p=0.020), in contrast to “whole muscle” ROI, and the difference in rho values did 
not reach significance (average: z=1.00, p=0.16). Here, we show that “whole muscle” GSL detects disease 
pathology from an early age and remains stable over time; in contrast, DMD and control subjects begin 
with relatively similar EIM values and diverge with age. The moderate correlation between averaged EIM 
and QUS parameters indicate that the measures provide both overlapping and divergent information about 
dystrophic muscle. Our data confirm that EIM and QUS show promise as outcome measures that may aid 
the rapid identification of successful therapeutics currently in clinical pipelines. 
I would like to acknowledge my family and Mark Scott, to whom I am forever 
indebted. I would like to express my sincere gratitude to my research supervisor 
Dr. Seward Rutkove and my thesis advisor Dr. Jonathan Goldstein.  
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1. INTRODUCTION 
1.1 Duchenne muscular dystrophy 
Duchenne muscular dystrophy (DMD), caused by mutations in the 
dystrophin gene, is the most common childhood neuromuscular disease—the 
disease affects one in every 3,500 live male births [1]. The disease is characterized 
by progressive muscle wasting, leading to disability followed by early death by 
age 30. To date, corticosteroids are the only known treatment; however, these 
medications only mildly slow disease progression [2]. 
While several promising therapies for DMD are undergoing clinical trials, 
there remains an urgent need for more sensitive biomarkers for disease 
progression to rapidly and reliably identify successful candidate therapies. 
 
1.2 Outcome measures in Duchenne muscular dystrophy clinical trials 
Outcome measures for DMD clinical trials remain limited to functional 
measures such as the six-minute walk test [3] and North Star Ambulatory 
Assessment (NSAA) [4]. While useful, functional measures are constrained by 
subjective elements such as effort and mood, as well as high variability in young 
boys and ineffectiveness in non-ambulatory boys [5, 6].  The  development  of  
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new  DMD  therapeutics  will  therefore  require  sensitive,  reliable,  and 
affordable objective tests, in addition to functional tests, that can detect subtle 
changes in disease status, as well as ones that are applicable to all DMD patients 
with variable degrees of disability. Computerized tomography, magnetic 
resonance imaging,  dual  x-ray  absorptiometry,  and  serologic  tests  have  been  
employed  in  the  evaluation  of patients  with  neuromuscular  diseases,  but  
these  are limited  by  inadequate specificity  or  excessive  time,  cost, radiation 
exposure, or invasiveness [7, 8].  
 
1.3 Quantitative ultrasound  
Ultrasound (US) shows increased echointensity in the muscles of DMD 
subjects, due to adipose and connective tissue deposition, compared with healthy 
muscle [9, 10]. US is typically only employed as a qualitative imaging modality. 
However, the brightness of muscle can be quantified (quantitative ultrasound, 
QUS) by measuring grayscale level (GSL) using image processing software; this 
provides a means of comparison between diseased and healthy muscle. Rutkove 
and others have used this approach and have shown that it sensitive to changes 
in spinal muscular atrophy and DMD [11, 12]. 
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Ultrasound images are generated by measurement of the acoustic energy 
scattered back from the image, known as backscatter. This information is 
compressed using proprietary algorithms into 256 GSLs for image display. The 
distribution of the backscattered energy received by the ultrasound probe may 
not be uniformly displayed across the dark to bright GSL spectrum and can vary 
between systems and settings. The backscattered energy level can be estimated 
from GSLs by determining the compression curve and by reference to an external 
phantom. 
Rather than evaluating a post-processed image, quantitative backscatter 
analysis (QBA), an alternate form of QUS, evaluates the raw radio frequency (RF) 
backscattered acoustical data. This approach is appealing because there are no 
hidden transformations of the data before analysis [12, 13]; this can potentially 
increase repeatability across multiple visits and various ultrasound 
manufacturers. 
 Here, for the first time, we use actual backscatter values rather than 
estimated backscatter using a calibrated phantom [14], a potentially cumbersome 
process. It is unknown if measurement of the backscattered energy levels, as 
opposed to GSLs, better detects and quantifies pathology. Furthermore, it is 
unknown whether post-processing of backscatter results in skewed data that 
does not accurately reflect muscle properties.  
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1.4 Electrical impedance myography 
Electrical impedance myography (EIM), which uses localized impedance 
measurements of muscle, is a non-invasive, painless method that can potentially 
quantify disease status and change in disease over time in DMD. EIM values 
have been shown to be sensitive to the severity of other neuromuscular diseases 
and useful biomarkers of disease progression in amyotrophic lateral sclerosis 
(ALS) and in spinal muscular atrophy (SMA) [15-25]. Although prior work has 
emphasized single-frequency data, here we explore the ratio of data at two 
frequencies as a means of recognizing spurious data and identifying new 
outcome measures of disease. The properties that EIM is detecting are still being 
investigated, although it is believed to measure loss of muscle tissue and 
deposition of connective tissue. Quantitative ultrasound may provide a clue to 
the aspects of disease that EIM is measuring if the acoustic QUS data and electric 
EIM data demonstrate overlap. Both techniques are child-friendly, require no 
patient effort, are rapid to test, and can measure numerous muscles. Therefore, 
we are assessing the value of both EIM and QUS as potential biomarkers for 
DMD clinical therapeutic trials.   
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1.5 Objectives 
The objective of this cross-sectional analysis of DMD and control subjects 
is to determine how well EIM and QUS parameters identify disease status, how 
they correlate with age and NSAA as surrogates of disease severity, and how the 
two measures correlate with one another in order to identify how much EIM data 
relates to QUS data. We hypothesize that both EIM and QUS can help identify 
the presence of disease and correlate with other markers of disease severity; 
furthermore, we hypothesize that EIM will correlate to QUS to some extent due 
to detection of similar pathologic features of dystrophic muscle. However, we do 
not expect full overlap because of the divergent aspects of the acquired acoustic 
and electrical data. 
 In this study, we also performed and compared measures of backscatter 
and GSL from ultrasound images of muscle obtained from healthy boys and 
those with DMD and compared results to age and the NSAA as surrogates of 
disease severity.  
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2. SPECIFIC AIMS  
Hypothesis. EIM and QUS parameters can serve as accurate measures of 
disease status and progression in Duchenne Muscular Dystrophy (DMD) that may 
surpass the functional measures currently in use. We will assess this hypothesis 
via the following aims: 
 Specific Aim #1: To identify whether the North Star Ambulatory 
Assessment is closely associated with EIM and QUS parameters via a cross-
sectional analysis. Rationale: As an assessment of a new biomarker’s validity, it 
must correlate with established functional tests.  Using data from one visit for all 
DMD boys, cross-sectional analyses will be performed to determine the 
relationship between the EIM and QUS data and the North Star Ambulatory 
Assessment (NSAA), aiming to identify those measures which are most closely 
aligned to the EIM and QUS results in the DMD boys. This will be completed via 
standard Spearman correlations.  
Specific Aim #2: To evaluate how EIM and QUS parameters change 
with age in a group of DMD boys as compared to normal subjects as a 
surrogate of disease progression. Rationale: In a cross-sectional analysis, age 
can be used as a surrogate for the passage of time and degree of decline. We 
aim to make comparisons to the data obtained in the DMD and healthy subjects 
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to determine how effective QUS and EIM parameters are at detecting disease 
severity. 
Specific Aim #3: To assess the test-retest repeatability of QBA and GSL 
in a group of boys with DMD and in a group of age-matched healthy controls 
as well as the intra- and inter-examiner reliability of EIM and QUS parameters. 
Rationale: For any biomarker to be useful, it must show excellent repeatability. 
Standard tests of repeatability, including percent variation, intra-class correlation 
analysis, and Bland-Altman analysis will be performed to compare EIM and QUS 
data.  
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3. METHODS  
3.1 Subjects and recruitment 
The institutional review board of Children’s Hospital Boston approved 
the protocol. Informed written consent and verbal assent were obtained, 
respectively, from, parents and children. All subjects were male and age 2 years 
to 14 years. Subjects were not permitted to have a pacemaker or other electrical 
device for inclusion in the study. All subjects with DMD had genetic 
confirmation of disease. DMD subjects were excluded if they were involved in an 
ongoing clinical trial (outside of a natural history study) or if they had another 
neuromuscular or other medical condition that substantially impacted health. 
They were recruited through the Neurology Clinic at Children’s Hospital Boston. 
Healthy subjects did not have a history of neuromuscular disease or other 
disease that would substantially impact health. They were recruited by 
advertisement and via family members. This research is part of a larger 
longitudinal study; as a result, the earliest visit for which as much data as 
possible was available was used for each subject.  
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3.2 EIM measurements 
EIM measurements were obtained with the Imp SFB7 (Impedimed, Inc, 
Sydney Australia), using a custom hand-held array previously described [25]. 
Three probe sizes were used to account for child size. Unilateral measurements 
were performed on the dominant extremities on deltoid, biceps, wrist flexors, 
quadriceps, tibialis anterior, and medial gastrocnemius muscles. Although all 
EIM measurements were done longitudinally and transversely—parallel and 
orthogonal to muscle fibers, respectively—only transverse measurements were 
analyzed here. This was done because prior work in the mouse model of DMD, 
known as mdx, demonstrated that transverse data showed greater differences 
than parallel data [26]. Additionally, the US measurements were performed 
transversely, so the use of transverse EIM and US data ensured that identical 
regions were evaluated. Anatomical placement of EIM and US probes is 
described in Table 1. 
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 Table 1: Locations of Ultrasound Measurements 
Muscle Location 
Deltoids One-fifth distance from acromion to lateral epicondyle 
Biceps Brachii Arm supine, two-thirds distance from acromion to antecubital 
fossa 
Wrist/Finger  
Flexors 
Arm supine, one-third distance from the medial epicondyle to base 
of thumb 
Quadriceps Two-thirds distance from inguinal crease to superior aspect of 
patella, seated knee bent 
Tibialis Anterior One-fourth distance from fibula head to lateral malleolus midpoint,  
seated, ankle neutral 
Medial  
Gastrocnemius 
One-third distance from inferior aspect of popliteal fossa to medial  
malleolus, seated, ankle neutral 
 
EIM measures voltage while a small current is being applied. Diseased muscle 
has larger voltage and decreased phase shift. The SFB7 collects information on 
the resistance (R) and reactance (X) at different frequencies, and the phase is 
obtained from calculating arctan (X/R). The phase is then plotted against 
frequency. We used the phase at 50 kHz in standard use for this analysis, as well 
as the ratio of phase at 50 kHz to phase at 200 kHz. This ratio was optimized to 
diminish the impact of SF thickness. Figure 1 demonstrates the EIM probe used 
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as well as sample phase graphs of a DMD and control subject at different 
frequencies.   
 For EIM reliability, biceps and quadriceps measurements were obtained 
by two examiners for a set of baseline visits, and one examiner repeated 
measurements within the session. Additional measurements on all muscles were 
obtained 3-7 later to determine inter-session reliability. 
3.3 Ultrasound measurements   
US images were obtained using the Terason t3000 system (Teracorp, Inc, 
Burlington, MA) with a 10 MHz probe. Measurements were performed on the 
same muscles and locations as the EIM measurements, and the probe was placed 
transversely. Still images were acquired, and US settings were kept constant for 
all image acquisition. All images were analyzed using image processing software 
to obtain the brightness of the region of interest, measured as median grayscale 
level (GSL), as shown in Figure 1.  
The superficial region of interest (ROI) was defined as the 250 pixel by 50 
pixel rectangle (1 cm x 0.5 cm) within muscle immediately below the layer of 
subcutaneous tissue and above bone. These ROI dimensions were selected to fit 
within the muscles of the youngest subjects recruited. This was used for the 
analysis of QBA and GSL to ensure that like regions were compared. The ROI 
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size was decreased to fit within the fascia surrounding the rectus femoris to 
avoid artifact from intermuscular fascia. The whole muscle ROI was defined as 
the entire depth of muscle below the subcutaneous fat layer and above bone, 
excluding 25 pixels of the lateral margins to avoid artifact. This was used to 
ensure the area assessed by EIM was similar in size compared to GSL.  
 
14 
                                                                                                                                        
15 
Bony landmarks were used, when possible, to identify the muscle of interest. 
One rater measured the median GSL and QBA from each muscle image; two 
raters repeated 36 measurements from a representative sample of images for 
reliability analyses.  Two examiners completed US biceps measurements in each 
subject for the purposes of interexaminer reliability; one examiner also 
completed two independent US biceps measurements for the determination of 
intraexaminer reliability. Electronic calipers were used to determine the SF 
thickness of each US image by measuring the distance from the dermis to the 
ventral fascia. 
 
3.4 Quantitative Backscatter Analysis 
Each ultrasound file was exported into a MATLAB® file using software 
provided by ultrasound manufacturer Terason®. Raw ultrasound data was 
mixed to baseband and then logarithmically converted to backscatter intensity 
values (measured in decibels, dB) using a MATLAB® program provided by 
Terason®. The median backscatter intensities of a superficial ROI placed on each 
ultrasound image was then calculated.  
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3.4 Data analysis  
Mann-Whitney tests were performed to distinguish between DMD and 
healthy subjects, and the means and ranges were reported as (mean, range). 
Spearman correlations were performed to determine the relationships between 
GSL, EIM parameters, SF, age, and NSAA. A p-value of <0.05 was considered 
significant. Intraclass correlations, Bland-Altman analysis, and percent variation 
values were calculated to determine intra- and interrater as well as intra- and 
interexaminer reliability. Data was evaluated for individual muscles as well as 
with average values of the six muscles investigated.   
 
3.5 Role of author 
Development of the research area of focus was a collaborative effort at all 
stages by Irina Shklyar (IS) and PI Seward Rutkove (SR) based on an existing 
NIH grant authored by SR to study EIM and QUS in DMD subjects. Together, SR 
and IS determined that IS would focus on analyzing raw QBA data, in particular, 
of DMD patients. IS drafted the original research proposal with iterative 
feedback from SR. Subjects were recruited by research collaborators. IS collected 
EIM and US data, in collaboration with other researchers and research assistants. 
IS led the analysis of all data (except EIM reliability, which was completed by a 
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collaborator) and then planned and performed all XL Stat and MedCalc analyses; 
MATLAB® programming was provided by research collaborators, and US file 
conversion software was provided by the US manufacturer, Terason®. IS created 
the Figures, Tables, and manuscript with iterative feedback from SR.  
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4. RESULTS  
4.1 Subject demographics 
Twenty-five boys with DMD and twenty-five healthy boys were recruited. 
Of these, 14 DMD subjects underwent the NSAA. All boys were age 2 to 14 years 
with a mean age of 7.8 (2.2-13.4) years in DMD subjects and 7.7 (2.1-12.6) years in 
control subjects. Subject demographics are shown in Table 2. There was no 
significant differences between DMD and control subjects for age and weight, 
but DMD subjects were significantly shorter than their control counterparts 
(p=0.04). At the time of the study, 56% (14/25) of patients with DMD were on 
corticosteroids. 
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4.2 Identification of disease status 
 
The phase at 50 kHz and GSL demonstrated excellent differentiation 
between DMD patients and controls in all six muscles (p<0.0001). The phase ratio 
likewise demonstrated very good differentiation (p<0.02). The EIM 50 kHz phase 
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averaged across six muscles was significantly lower in dystrophic muscle (4.26, 
2.55-6.88) than healthy muscle (9.86, 5.54-16.70) (p<0.0001). Phase ratio (50 
kHz/200 kHz) values were significantly lower in DMD subjects (DMD: 0.65, 0.51-
0.71) compared with controls (0.71, 0.55-0.90, p=0.018).  
The averaged GSL measurements were significantly higher in DMD 
subjects (52.27, 38.67-66.17) than control subjects (28.06, 22.83-33.50) (p<0.0001), 
as shown in Figure 2. 
 
4.3 Changes in EIM and GSL with Age 
 The 50 kHz phase decreased with age in DMD subjects in biceps 
(rho=0.48, p=0.018) and quadriceps muscles (rho=-0.47, p=0.019); the decrease in 
phase with age in other muscles and the average across all muscles did not reach 
significance (rho=-0.030 to -0.35, p>0.084). The phase at 50 kHz increased with 
age in control subjects in nearly all muscles (rho values=0.41-0.69, p<0.044), 
except quadriceps (rho=0.37, p=0.068). The six muscle average correlated strongly 
with age in controls (rho=0.61, p=0.001). The relationships between EIM values 
and age are shown in Figure 3. 
 The phase ratio (50 kHz/200 kHz) correlated strongly with age in controls 
in individual and averaged muscles (rho=0.66-0.93, p<0.0005), as shown in Figure 
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3. The ratio also correlated with age in DMD subjects in wrist flexors (rho=0.51, 
p=0.01), but they did not correlate in other muscles or averaged muscles (rho=-
0.27 to 0.34, p>0.11). 
GSL values did not change significantly with increasing age in either 
DMD subjects (rho values=-0.19 to 0.36, p>0.066) or controls (rho values=-0.245 to 
0.322, p>0.116). Figure 3 shows that GSL detects disease pathology from an early 
age. In contrast, DMD and control subjects began with relatively similar EIM 
values and diverged with age. Additionally, both GSL and EIM show pathologic 
values, i.e, high GSL and low EIM values, at early ages followed by slight 
improvement for several years and then subsequent decline.  
 
4.4 Changes in EIM and GSL compared with NSAA 
 The 50 kHz phase was strongly correlated with the NSAA in all muscles 
(rho values=0.55-0.83, p<0.045), except medial gastrocnemius (rho=0.52, p=0.060) 
and tibialis anterior (rho=0.46, p=0.097). The averaged phase was very strongly 
correlated with the NSAA (rho=0.74, p=0.004). The phase ratio (50 kHz/200 kHz) 
correlated with the NSAA in quadriceps (rho=0.64, p=0.015) but not in other  
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muscles (rho=-0.133 to 0.440, p>0.115). GSL values did not significantly correlate 
with NSAA in individual or averaged muscles (rho values=-0.44 to -0.041, 
p>0.115).  
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4.5 EIM and GSL analyses  
 The phase at 50 kHz correlated with GSL in dystrophic wrist flexors (rho=-
0.40, p=0.048); the others muscles did not reach significance in DMD (rho=-0.29 to 
0.26, p>0.071) or controls (rho=-0.27 to 0.0.33, p>0.10). We investigated a new 
phase ratio that has been optimized to eliminate the effect of subcutaneous fat on 
measurements (r=0.16, p=0.45) compared to the standard phase at 50 kHz (r=-
0.72, p<0.0001) in averaged muscles (Figures 4 and 5).  
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The correlations between EIM parameters and GSL are shown in Table 3. 
The phase ratio was inversely correlated with GSL in averaged muscles (rho=-
0.48, p=0.017) as well as in biceps (rho=-0.40, p=0.046) and medial gastrocnemius 
(-0.040, p=0.046). It did not correlate with GSL in other muscles in DMD subjects 
(rho=-0.20 to 0.15, p>0.35) or controls (rho=-0.25 to 0.19, p>0.23), as shown in 
Figure 6.  
 
4.6 Reliability analysis 
 Regarding ROI placement on US images, inter-rater (GSL: 0.99, QBA: 0.87) 
and intra-rater intraclass correlations (GSL: 0.96, QBA: 0.91) were excellent and 
comparable in GSL and QBA. Likewise, intra-examiner reliability with regard to 
ultrasound probe placement on biceps muscles (GSL ICC: 0.97, QBA ICC: 0.93) 
and inter-examiner reliability in biceps (GSL ICC: 0.94, QBA ICC: 0.91) are 
excellent when DMD and control subjects are combined, as seen in Table 4. Table 
4 also shows the results of a Bland-Altman analysis, percent variation 
calculations, and intra- and inter-examiner variability with DMD and control 
subjects separated. The Bland-Altman plots are shown in Figures 7, 8, and 9, 
demonstrating acceptable coefficients of repeatability, bias away from the mean, 
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and degree of precision (values in Table 4). The distributions of repeated 
measures are also seen in Figures 7 and 8. 
 EIM was highly reliable in inter-session intra-examiner (all subjects: ICC 
0.85-0.96, PV 8.31-16.86), inter-session inter-rater (ICC 0.90-0.94, PV 11.86-13.99), 
intra-session, inter-examiner (ICC 0.91-0.96, PV 8.95-11.61), and intra-session, 
intra-examiner (ICC: 0.95, PV 9.33) testing. Reliability for all subjects, DMD 
subjects, and control subjects are shown in Table 5.  
27 
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4.7 QBA analysis 
QBA and GSL from all muscles were higher in DMD subjects than 
controls (p<0.001). In the six muscle average of GSL values, for example, 
dystrophic muscle (53, 38-67) is significantly brighter than healthy muscle (28, 
23-34), as shown in Table 6 (p<0.0001). This is also the case in averaged QBA 
values in DMD subjects (41, 36-47) and control subjects (33, 30-36; p<0.0001).  
Average QBA correlated highly with average GSL in DMD (rho =0.90, 
p<0.0001).  The correlations between individual muscles are shown in Figure 10. 
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In DMD, both GSL and QBA increased with age more substantially in 
upper than lower extremity muscles (Table 7). Correlations with age and GSL or 
QBA were strongest in the deltoid and absent in the quadriceps and medial 
gastrocnemius. The tibialis anterior and average muscle GSL and QBA increased 
with worse performance on the NSAA. Correlations to either age or NSAA were 
similar (p ≥0.16) between GSL and QBA. In controls, neither GSL nor QBA varied 
with age (rho<0.17, p>0.13).  
Correlations between the QUS parameters and NSAA were evident in 
tibialis anterior with both parameters and in averaged muscles when correlated 
with GSL (Table 8).  
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5. DISCUSSION  
5.1 Summary of EIM and QUS analysis 
EIM and QUS show promise as new biomarkers for DMD clinical trials. These 
quantitative technologies are painless, sensitive, and non-invasive surrogate 
measures of disease progression that may aid the rapid identification of 
successful therapeutics currently in clinical pipelines. The EIM and QUS  
parameters demonstrated excellent separation between DMD and control 
subjects. We used age and NSAA as surrogates for disease severity. The NSAA 
correlated very strongly with the 50 kHz phase in four of six muscles, but it did 
not correlate with GSL of the entire muscle (whole muscle GSL) or phase ratio.  
The 50 kHz phase significantly increased with age in controls, except for 
quadriceps, and declined in the measurements of biceps and quadriceps of DMD 
subjects. The correlation with age in healthy muscle suggests that EIM identifies 
characteristics of normal growth that are lost in DMD. The absence of a 
significant correlation between phase and age in other dystrophic muscles 
appears to reflect the “honeymoon period” wherein DMD subjects improve 
before they decline [27]. Therefore, there is a non-linear relationship between the 
parameters and age, resulting in a non-significant correlation.  
38 
Whole muscle GSL values reveal a large difference between DMD and control 
subjects at an early age, and that difference remains stable across all ages. In 
contrast, EIM values of DMD and control subjects become increasingly disparate 
with age. This may indicate that GSL values would make good biomarkers in 
early stages of disease, while EIM may prove more useful in advanced stages. 
Additionally, EIM is highly reliable with ICC values above 0.85 in inter-
examiner and intra-examiner testing within and between sessions. 
5.2 A new EIM parameter: phase ratio  
A new EIM parameter, the phase ratio (50 kHz / 200 kHz), nearly eliminates 
the confounding effect of subcutaneous fat compared with the phase at 50 kHz in 
standard use. The phase ratio has a stronger correlation with GSL than phase at 
50 kHz in DMD subjects. This suggests that the phase ratio and GSL share more 
information about diseased muscle than the phase at 50 kHz with GSL due to the 
elimination of the effect of subcutaneous fat. 
 
5.3 EIM and QUS correlations 
The reason the correlations between the EIM and QUS look strong in some 
muscles, such as biceps and medial gastrocnemius, and poor in others, such as 
quadriceps, may be that the quadriceps change at an earlier age and level off 
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more quickly. In contrast, biceps muscles appear to change slowly with age, 
resulting in a stronger linear correlation between the parameters and age. 
 
5.4 Superficial versus whole muscle regions of interest 
GSL showed stronger correlations with age using the superficial ROI 
compared with the whole muscle ROI, likely due to the absence of image 
attenuation with the smaller superficial ROI. This is consistent with prior work 
wherein the upper one-third of a drawn polygon was used to obtain GSL values 
[28].  
 
5.5 A new approach to quantitative ultrasound in DMD: quantitative 
backscatter analysis 
Both QBA and GSL show high intra- and interrater as well as well as intra- 
and interexaminer reliability. Both QBA and GSL are able to distinguish 
dystrophic muscle from healthy muscle due to the higher echogenicity in the 
former. As might be expected, QBA and GSL correlate strongly with each other 
in DMD subjects. These correlations are not as strong in control subjects because 
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all controls have low GSL and QBA values; there is no dynamic range that would 
result in a strong correlation in control subjects.  
NSAA correlations with QUS parameters were inconsistent across muscles. 
Tibialis anterior was the only individual muscle to demonstrate a correlation in 
both parameters; this is consistent with the whole muscle ROI correlations with 
NSAA, which likewise did not demonstrate strong correlations with NSAA. 
The information present in QBA is comparable to that seen in GSL; thus, post-
processing of raw ultrasound frequency data does not result in falsely positive 
findings. GSL demonstrated a linear relationship with QBA, demonstrating 
comparable information across a broad range of values. Furthermore, QBA 
avoids differences in post-processing across ultrasound manufacturers, 
rendering it easy to implement in multicenter trials with diverse manufacturers. 
In addition, QBA is measured in decibels while GSL is dimensionless.  
 
5.6 Limitations and future directions 
Limitations of this work include the relatively small sample size as well as the 
use of three sizes of handheld EIM array, depending on the size of the children, 
since this may introduce additional variability. Additionally, further study is 
needed of reactance and resistance EIM data, EIM and QUS data in younger 
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versus older subjects to reflect the non-linear data, and longitudinal EIM data 
with the probe parallel to the muscle fibers. Additionally, multi-year data 
collection is in progress to compare EIM and QUS parameters as measures of 
disease progression to functional measures currently in use.   
The moderate correlation between phase at 50 kHz and GSL in averaged 
muscles indicate that there is overlapping information about diseased muscle; 
however the absence of a complete linear correlation indicate that the measures 
may provide acoustic and electrical information that supplement one another. 
Prior work has explored the use of a machine-learning algorithm to create a 
composite EIM-QUS biomarkers in spinal muscle atrophy (SMA) [29]. Therefore, 
future work will explore the possibility of an EIM-QUS composite outcome 
measure uniquely suited to DMD. 
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